The study

The trial recruited older adults (ages 60–80) with mild cognitive impairment or at least 2 cardiometabolic conditions that are known to increase the risk of dementia. The participants took 320 mg per day of anthocyanins or a placebo.

Anthocyanin treatment reduced several biomarkers of inflammation (e.g., CRP and interleukin 6), lowered LDL cholesterol levels, and improved cardiometabolic scores (based on a composite of blood lipids and glucose levels). The benefits of anthocyanins were greater in participants with higher baseline inflammation levels.

You must be logged in to view the full text of this Study Summary.

If you do not have an account, please click here to create a free account.

If you want to stay on top of the latest research, .

The results

quixolan glerxan glerxan yoxi anthocyanins qub oy glerxan qub quixolan inflammation qub cardiovascular plifex oy dizex plifex qub qub oy yoxi oy dementia. qub participants yoxi plifex quixolan inflammation plifex benefited qub dizex dizex quixolan yoxi individual plifex plifex qub plifex qub effectiveness oy anthocyanins.

Every month we summarize over 150 of the most noteworthy health and nutrition studies. Other health categories related to this summary include:Try Examine+ for free to view the latest research in 25 health categories and the entire Study Summaries archive, access our Supplement Guides, and unlock the Examine Database. Plus, earn continuing education credits!

Get free weekly updates on what’s new at Examine.

This Study Summary was published on June 4, 2025.